Morphotek, Inc., a subsidiary of Eisai Inc., has acquired certain assets to a tumor-targeting platform from TransMolecular, Inc. (TMI) for an undisclosed upfront payment and development milestones. The tumor-targeting peptide (TTP) platform delivers conjugated radionucleotides, chemotoxins, nanoparticles and optical dyes to tumor cells via systemic administration. The TTP technology has been validated in multiple preclinical and clinical trials demonstrating tumor-specific delivery of conjugated...